Illustrative image.

Rituxan

Name: Rituxan
Brand: Celltrion
Availability: InStock

Rituximab

Prescription required

$1460.00

500mg/50ml · 1 vial · 6 months supply

BrandBranded medicine· By Celltrion

$243.33 per month

Strength

How long a supply?

6 months$243.33 a monthOne-off$1460.00

Supplied from Israel

Test mode: no payment is taken. View cart

Ships cold, in insulated packing

This medicine ships in insulated packing with coolant and carries its own shipping charge, shown at checkout.

Annual cost

$2920a year at this pack size

Prescription required

Upload your prescription after ordering, or send it to our pharmacy team. We dispense only against a valid prescription.

100mg/10ml

100mg

500mg/50ml

1400mg/11.7ml

FDA boxed warningFatal infusion-related reactions, severe mucocutaneous reactions, hepatitis b virus reactivation and progressive multifocal leukoencephalopathy

Fatal infusion-related reactions within 24 hours of RITUXAN infusion; approximately 80% of fatal reactions occurred with first infusion. Monitor patients and discontinue RITUXAN infusion for severe reactions.

Severe mucocutaneous reactions, some with fatal outcomes.

Hepatitis B virus (HBV) reactivation, in some cases resulting in fulminant hepatitis, hepatic failure, and death.

Progressive multifocal leukoencephalopathy (PML) resulting in death.

Read this with the rest of the clinical information

About Rituxan

Overview

Rituxan (rituximab) is a monoclonal antibody medicine given by intravenous infusion. It treats certain CD20-positive B-cell non-Hodgkin lymphomas and chronic lymphocytic leukemia, with chemotherapy or on its own depending on the specific condition. It is also used with methotrexate for adults with moderately to severely active rheumatoid arthritis after an inadequate response to one or more TNF-blocking treatments, with glucocorticoids for granulomatosis with polyangiitis and microscopic polyangiitis in patients aged 2 years and older, and for moderate to severe pemphigus vulgaris in adults. It works by attaching to a protein called CD20 on certain B cells, causing these cells to break down.

What it treats

- Certain CD20-positive B-cell non-Hodgkin lymphomas in adults, used alone or with chemotherapy depending on the lymphoma type and treatment history. - Previously untreated, advanced-stage, CD20-positive diffuse large B-cell lymphoma, Burkitt lymphoma, Burkitt-like lymphoma or mature B-cell acute leukemia in children aged 6 months and older, with chemotherapy. - CD20-positive chronic lymphocytic leukemia in adults, whether previously treated or untreated, with fludarabine and cyclophosphamide. - Moderately to severely active rheumatoid arthritis in adults who have had an inadequate response to one or more TNF antagonist treatments, with methotrexate. - Granulomatosis with polyangiitis and microscopic polyangiitis in adults and children aged 2 years and older, with glucocorticoids. - Moderate to severe pemphigus vulgaris in adults.

Safety information

Side effects

Common side effects vary by the condition being treated. They include reactions during an infusion, fever, chills, infections, weakness, and low levels of certain white blood cells. Other common effects include nausea, diarrhea, headache, muscle spasms, anemia, swelling of the hands or feet, and depression. Respiratory infections, bronchitis, and urinary tract infections are also reported. In children receiving Rituxan with chemotherapy for certain B-cell cancers, commonly reported severe reactions include fever with low white blood cell counts, inflammation of the mouth or intestines, sepsis, increased liver enzymes, and low blood potassium. Serious side effects warrant immediate medical attention. These include severe infusion reactions; severe skin and mucous membrane reactions; hepatitis B reactivation with severe liver inflammation; progressive multifocal leukoencephalopathy, a serious brain condition; tumor lysis syndrome, involving rapid breakdown of cancer cells; serious infections; heart problems; kidney damage; and bowel blockage or perforation. Contact a doctor immediately for abdominal pain, vomiting, reduced urine output, or suspected serious infection or infusion reaction. Rituxan can harm an unborn baby. Contact your doctor if you become pregnant during treatment. Effective contraception is advised for those who could become pregnant.

FDA boxed warning

Fatal infusion-related reactions, severe mucocutaneous reactions, hepatitis b virus reactivation and progressive multifocal leukoencephalopathy

Severe mucocutaneous reactions, some with fatal outcomes.

Hepatitis B virus (HBV) reactivation, in some cases resulting in fulminant hepatitis, hepatic failure, and death.

Progressive multifocal leukoencephalopathy (PML) resulting in death.

A boxed warning is the strongest warning the US Food and Drug Administration requires on a medicine label. Text is taken from the official label, with internal section references removed.

When to call your doctor

- Seek medical attention immediately for abdominal pain or vomiting. - Get urgent medical help if you pass much less urine than usual. - Seek immediate care for severe reactions affecting your skin or the lining of your mouth. - Get medical help immediately for fever or chills, particularly during or after an infusion.

If symptoms are severe or getting worse quickly, seek emergency care rather than waiting.

Before taking this medicine

The supplied FDA label lists no formal contraindications for Rituxan. However, it includes important warnings and precautions: - Tumor lysis syndrome: requires intravenous hydration, medicines to lower uric acid, and kidney function monitoring. - Infections: Rituxan should be withheld while appropriate anti-infective treatment is given. - Serious or life-threatening heart reactions: the infusion must be stopped. - Kidney toxicity: treatment must be stopped if blood creatinine rises or urine output becomes very low. - Bowel blockage or perforation: abdominal pain, vomiting, or related symptoms require evaluation. - Vaccination: live virus vaccines are not recommended before or during treatment. - Pregnancy: Rituxan can harm an unborn baby. Effective contraception is advised for females who can become pregnant. - Breastfeeding: do not breastfeed during treatment. For patients with chronic lymphocytic leukemia (CLL) older than 70, exploratory analyses suggest no benefit from adding Rituxan to FC treatment.

Interactions

Kidney toxicity can occur when Rituxan is used with cisplatin. Tell your doctor if you are receiving cisplatin. Formal drug interaction studies have not been performed with Rituxan. In patients with chronic lymphocytic leukemia (CLL), Rituxan did not change exposure to fludarabine or cyclophosphamide. In rheumatoid arthritis (RA) trials, methotrexate or cyclophosphamide did not change how the body processed rituximab.

Using Rituxan

Dosing

Dosing is set by your prescriber. Each health care professional may prescribe medication differently according to a patient's medical history and condition, so follow the directions on your prescription label and speak to your doctor or pharmacist before changing anything.

Storage

Store in the original carton below 25°C, protected from light, unless the pack states refrigeration. Do not freeze. Keep all medicines out of the sight and reach of children.

Clinical information on this page is summarised from the US FDA label RITUXAN (RITUXIMAB) INJECTION, SOLUTION [GENENTECH, INC.] (DailyMed, retrieved 19 September 2026).

Reviews

No reviews yet. Mail Order Drugs opened recently, and we publish reviews only from verified customers of this site, so this space stays empty until real ones arrive.